The independent clinical trial, conducted by Locus Medicus in Athens, Greece, prospectively tested 330 patients with symptomatic and asymptomatic cases of COVID-19.
For the study, staff at the clinical laboratory collected two bilateral anterior nasal swabs from each patient. Immediately after collection, one swab was tested in the lab's standard of care CE-Mark RT-PCR test and the other swab was tested by BiologyWorks k(now).
Results from the BiologyWorks k(now) molecular test were 99.1% in overall % agreement with the results of the RT-PCR lab tests.
In addition to the clinical trial conducted by Locus Medicus, other independent validation studies of BiologyWorks k(now) have been conducted by the University of California, Los Angeles, the Los Angeles County Department of Health Services and Streeklab in Haarlem, Netherlands.
Moreover, the company verified the efficacy of BiologyWorks k(now) with over 12,000 tests in its Southern California lab.
These studies also validate that the BiologyWorks k(now) molecular COVID-19 test provides RT-PCR lab quality results, the company said.
BiologyWorks' molecular test works in conjunction with the k(now) PRO digital platform, which provides point-of-care providers with a complete solution for end-to-end testing management. POC providers and patients simultaneously receive verified results within 45 minutes, giving individuals control of their health data.
The BiologyWorks k(now) PRO digital platform complies with the privacy standards, including the Health Insurance Portability and Accountability Act (HIPAA) and the EU General Data Protection Regulation.
BiologyWorks is the creator of BiologyWorks k(now) molecular test and the k(now) PRO digital platform.
Together, these products offer point-of-care providers with a solution for testing management.
The company's chemistry is patent-protected, based on research originating with the Alfred Mann Foundation, and is underwritten by a grant from the Bill and Melinda Gates Foundation.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA